- Oak Hill takes SPAC track to Nasdaq with Roche asset in towOak Hill Bio is developing the antisense therapy rugonersen, which it licensed from Roche in 2025, for Angelman syndrome.
- After PCOS became PMOS, there’s hope for new awareness among Black and Latina womenGrowing awareness of a painful endocrine disorder now named PMOS is good news for women of color, who have high prevalence and low diagnosis.